Company Overview of Venrock
Venrock is a venture capital and private equity firm specializing in seed, early stage, late-stage, mezzanine, growth capital, and first round investments. The firm may also consider second round investments. It primarily invests in information technology, healthcare, media, and energy and nanotechnology, agtech, biofuels, specialty pharmaceuticals, animal health, biotechnology, drug discovery and development, life sciences, material sciences, digital media and mobile, Internet, Ad Tech, Generics, consumer and consumer health, consumer technology and electronics, enablers, healthcare information technology and services, diagnostics, medical devices, cloud-centric technologies, crowd, fintech...
530 Fifth Avenue
New York, NY 10036
Founded in 1969
Key Executives for Venrock
Partner and General Partner
Partner and General Partner
Compensation as of Fiscal Year 2015.
Venrock Key Developments
Mevion Medical Systems, HOPU Investments, YuanMing Capital, Caxton Alternative Management L.P., ProQuest Investments, Venrock and CHL Medical Partners Forms Joint Venture to Produce, Sell and Service Proton Therapy Systems for the Chinese Market
Aug 4 15
Mevion Medical Systems announced that it has entered into an investment agreement where up to $200 million will be invested in Mevion to accelerate its worldwide expansion. The investment was led by HOPU Investments, YuanMing Capital, and participated in by other Chinese investors and existing U.S. investors Caxton Alternative Management L.P., ProQuest Investments, Venrock and CHL Medical Partners. Concurrent with the investment, Mevion and the lead investors will form a joint venture in China to produce, sell and service proton therapy systems for the Chinese market. HOPU and YuanMing have extensive experience investing in successful healthcare companies and offer a significant network of healthcare experience in China.
Venrock Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 through Nov-13-2014
Oct 27 14
Venrock Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 through Nov-13-2014. Venue: Apella, 450 East 29th Street, New York, New York, United States. Presentation Date & Speakers: Nov-12-2014, Camille D. Samuels, Partner. Nov-13-2014, Camille D. Samuels, Partner.
Venrock Announces Executive Appointments
May 15 14
Venrock announced that Camille Samuels and Doug Dooley have joined the investment team, both in the Palo Alto office. As a Partner, Samuels brings over a decade of venture investing experience to Venrock and will continue her efforts in biotech and consumer health, while expanding her focus to later stage healthcare companies. Formerly an entrepreneur, Dooley will focus on infrastructure technologies and cloud-centric software. Previously, Samuels was a Managing Director at Versant Ventures where she invested in Achaogen (AKAO), Kythera (KYTH), and Novacardia (acquired by Merck), among others. Prior to Versant, she was responsible for business development at Tularik Inc. (acquired by Amgen) and also spent time at Genzyme, Millennium Predictive Medicine and LEK Consulting. Dooley builds on a two-decade career at infrastructure technology companies ranging from large corporations like Cisco and Intel to security and virtualization startups like Neoteris, NetScreen, and RingCube.
Similar Private Companies By Industry
Recent Private Companies Transactions